An interventional study of iCover balloon-expandable covered peripheral stent system as bridging stent in Complex Abdominal Aortic Aneurysms, sponsored by iVascular S.L.U.. Recruiting at 24 sites in 5 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by iVascular S.L.U. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Aortic Aneurysm, Abdominal with a site in France — 10 open to participants now, 13 under way, none of them phase 3. Aortic Aneurysm, Abdominal · France.
Among the 59 studies in Aortic Aneurysm, Abdominal with a site in France, this one is the 12th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2026, is one of 22 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 58th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →10 of the 59 studies in Aortic Aneurysm, Abdominal with a site in France are open now. Recruiting first, the newest first:
Groupe Hospitalier de la Rochelle Ré Aunis · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 50–75 · Men only · Healthy volunteers
Rijnstate Hospital · Sites in France, United States, Germany and 5 more countries
Ages 18+
Medtronic Cardiovascular · Sites in France, United States, Finland and 9 more countries
Ages 20+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 66 across 228 interventional studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 103 across the 26 interventional studies, 181 across the 33 observational. Of the 38 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 59 have an industry lead sponsor. The 10 most frequent:
iVascular S.L.U. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
iVascular S.L.U. has 2 studies filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
3 of the studies in Aortic Aneurysm, Abdominal with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05378347Medtronic CardiovascularEndurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial | 2027-05 |
| NCT06029660Shape Memory Medical, Inc.AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion | 2027-07 |
| NCT05617326Fondation Ophtalmologique Adolphe de RothschildScreening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies in Aortic Aneurysm, Abdominal with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
fenCo is a European multicentre, prospective study to evaluate the use of the iCover covered stents as bridging stents for reno-visceral target vessel during fEVAR for the treatment of complex abdominal aortic aneurysms.
In terms of complex endovascular repair, fenestrated stent grafts should be considered the preferred treatment option when feasible. The main advantage of Fenestrated Endovascular Aneurysm Repair (fEVAR) lies in the avoidance of aortic cross clamping and subsequent lower risk of renal dysfunction, less surgical trauma and faster recovery, which may be advantageous for patients at high risk for open surgery. fenCo study aims to demonstrate the safety and efficacy of iCover when used as bridging stent in fEVAR procedures for the treatment of complex abdominal aortic aneurysms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Anatomy and patient strictly in accordance with the Instructions For Use (IFU) of the fenestrated endograft chosen to be implanted:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iCover balloon-expandable covered peripheral stent system
Device: iCover balloon-expandable covered peripheral stent system as bridging stent
This device will be used as bridging stent during FEVAR (fenestrated endovascular aortic repair) procedures.
Bridging stent patency at 12-month visit
Defined as rate of stents with an absence of binary restenosis (≥ 50% stenosis) based on CT Angio at 12 months visit (+/-2 months).
Time frame: 12 months visit
Absence of target vessel instability between implantation and 12-month visit.
Defined as rate of patients with an absence of target vessel instability described as a composite endpoint of any branch-related complication leading to: aneurysm rupture/ death/ occlusion/ component separation/ or reintervention to maintain branch patency or to treat a branch-related component separation or endoleak between implantation and 12 months visit (+/-2 months).
Time frame: starting at implant day through the study completion, with an average of 12Months up to 14Months per window.
Technical success: Successful introduction and deployment of the iCover stent implanted as bridging stent in FEVAR procedure.
Defined as rate of stents with successful introduction and deployment of the iCover (iVascular) implanted as bridging stent in FEVAR.
Time frame: During the index procedure (from stent introduction to final deployment, up to procedure completion)
Bridging stent patency at the first postoperative imaging, at 6 and at 12 months visits.
Defined as rate of stents without binary restenosis \> 50% or occlusion on duplex scan and/or angioCT scan examination, or angiography at discharge at 6 and 12 months visits.
Time frame: at discharge visit (up to 3 months, average of 7days) and at 6 and 12 months visits ( can be up to 8 and 14months from implant day)
Absence of endoleaks linked to iCover covered stent defects at the first postoperative imaging, at 6 and 12 months visits.
Defined as rate of stents without endoleaks linked to iCover covered stent defects (Malposition, rupture or disconnection) on Duplex scan, angio CTscan or angiography at discharge visit, at 6 months visits and at 12 months visit.
Time frame: discharge visit , 6 and 12 months visits.
Absence of re-intervention due to a technical defect in iCover covered stents at discharge, at 6 months visit, and at 12 months visit.
Defined as rate of stents without re-intervention due to a technical defect in iCover covered stents post-procedure between surgery and post operative to discharge period, between surgery and 6 months visit, between surgery and 12 months visit.
Time frame: between surgery and post operative to discharge period, between surgery and 6 months visit, between surgery and 12 months visit.
Absence of type I or III endoleaks post-procedure at the first postoperative imaging, at 6 and 12 months visits.
Defined as rate of stents without type I or III endoleaks post-procedure on duplex scan, angio CTscan or angiography at discharge period, 6 months visit and at 12 months visit.
Time frame: discharge visit, 6 and 12 months visits.
30-day post-procedure mortality.
Defined as rate of post-procedure mortality (all causes) within 30-day post procedure.
Time frame: within 30 days post procedure
In-hospital post-procedure mortality (all causes).
Defined as rate of In-hospital post-procedure mortality (all causes).
Time frame: between procedure and 12 months visit
Absence of aortic endograft migration at 6 months visit and at 12 months visit.
Defined as rate of endografts without aortic migration \> 10 mm at 6 Months visit and 12 months visit.
Time frame: at 6 and 12 months visits
No increase in maximum aneurysmal sac diameter measured by CT angiography at 6 and at 12 months visits.
Defined as rate of patients without increase of \> 5 mm in maximum aneurysmal sac diameter compared with post-procedure angio CT scan measured by angio CT scan at 6 and 12 months visits.
Time frame: at 6 and 12 months visits
Absence of post-procedural aortic surgical conversion at discharge, at 6 and 12 months visits.
Defined as absence of post-procedural aortic surgical conversion between the implantation and the follow-up visits
Time frame: between implant and 6 and 12 months visits
Absence of aneurysm-related mortality post-procedure at discharge, at 6 months and 12 months visits.
Defined as absence of aneurysm-related mortality post-procedure between the implantation and the follow-up visits.
Time frame: between implant and 6 and 12 months visits
Absence of aneurysm related secondary endovascular procedures at discharge, at 6 and 12 months visits.
Defined as absence of aneurysm related secondary endovascular procedures between the implantation and the follow-up visits.
Time frame: between implant 6 and 12 months visits.
Absence of major adverse events (MAEs) at discharge, at 6 and 12 months visits.
Defined as aortic rupture, aneurysm-related death, in-hospital death, decline in renal function (by at least 20%), lower extremity ischemia, mesenteric ischemia, or unplanned reintervention between the implantation and the follow-up visits.
Time frame: between implant and 6, 12 months vists.
Absence of target vessel instability at 12 months visit.
Absence of target vessel instability at 12 months visit.
Time frame: at 12 months visit
Target vessel patency at at 6 and 12 months visits
Defined as proportion of target vessel patency at 6 and 12 months.
Time frame: 6 and 12 months visits
Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.
Of 43 industry-sponsored interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 73. This study's planned 28 months is below that.
Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.